Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
View original at finance.yahoo.comWeek 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) Ascendis Pharma – Once-weekly TransCon® CNP and TransCon® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) e…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Once-weekly TransCon CNP has demonstrated its potential to transform the treatment of achondroplasia, positioning it as a potential long-term foundation of care
80% confidenceCombination therapy with TransCon CNP and TransCon hGH may set new treatment standards with clinically meaningful improvements in growth, body proportionality, and arm span with a safety and tolerability profile essential for long-term use in children
80% confidenceThe combination data underscore the potential of TransCon CNP to become the backbone therapy for addressing the underlying biology of achondroplasia, with TransCon hGH providing complementary benefit
80% confidenceData like COACH trial results may help expand the range of options individuals and families consider as they weigh what matters most to them in achondroplasia treatment
80% confidenceIt is encouraging to see meaningful improvements in arm span and body proportionality alongside changes in linear height, as these endpoints provide important context beyond height alone
80% confidenceThe COACH Trial has demonstrated unmatched improvements in growth and benefits beyond linear growth without compromising safety or tolerability compared to historical data
80% confidenceRational dual-agent regimens such as TransCon CNP and TransCon hGH combination may become a new standard of care in achondroplasia and other growth disorders
80% confidence